HIV-derived vectors for therapy and vaccination against HIV

Area of Science:

• Virology
• Gene Therapy
• Immunology

Background:

• Human Immunodeficiency Virus (HIV) presents a significant global health challenge.
• The inherent gene delivery capabilities of HIV can be repurposed for therapeutic applications.
• Lentiviral vectors (LVs) are engineered from HIV, retaining essential gene delivery functions while removing pathogenic elements.

Purpose of the Study:

• To review the current generation of lentiviral vectors (LVs).
• To focus on the application of LVs in vaccine development against HIV/AIDS.
• To summarize preclinical data and ongoing optimization efforts for LV-based vaccines.

Main Methods:

• Engineering of HIV-derived lentiviral vectors (LVs) by retaining cis-active sequences for nuclear delivery.
• Exclusion of viral replication and pathogenesis coding sequences from the LV genome.
• In trans provision of necessary viral proteins for lentivector particle formation and early replication steps.

Main Results:

• HIV-derived vectors are non-replicative and highly efficient in delivering genes of interest into target cells.
• Preclinical data for LV-based vaccines against HIV/AIDS are highly encouraging.
• Ongoing research focuses on optimizing LV safety and immunogenicity.

Conclusions:

• Lentiviral vectors represent a promising tool for gene therapy and vaccination strategies against HIV/AIDS.
• The efficient gene delivery mechanism of LVs offers a novel therapeutic avenue.
• Further optimization of LVs is crucial for enhancing their safety and efficacy in clinical applications.